These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 35041467)

  • 1. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.
    Eisen A; Somerfield MR; Accordino MK; Blanchette PS; Clemons MJ; Dhesy-Thind S; Dillmon MS; D'Oronzo S; Fletcher GG; Frank ES; Hallmeyer S; Makhoul I; Moy B; Thawer A; Wu JY; Van Poznak CH
    J Clin Oncol; 2022 Mar; 40(7):787-800. PubMed ID: 35041467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.
    Dhesy-Thind S; Fletcher GG; Blanchette PS; Clemons MJ; Dillmon MS; Frank ES; Gandhi S; Gupta R; Mates M; Moy B; Vandenberg T; Van Poznak CH
    J Clin Oncol; 2017 Jun; 35(18):2062-2081. PubMed ID: 28618241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.
    Van Poznak C; Somerfield MR; Barlow WE; Biermann JS; Bosserman LD; Clemons MJ; Dhesy-Thind SK; Dillmon MS; Eisen A; Frank ES; Jagsi R; Jimenez R; Theriault RL; Vandenberg TA; Yee GC; Moy B
    J Clin Oncol; 2017 Dec; 35(35):3978-3986. PubMed ID: 29035643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.
    Hillner BE; Ingle JN; Berenson JR; Janjan NA; Albain KS; Lipton A; Yee G; Biermann JS; Chlebowski RT; Pfister DG
    J Clin Oncol; 2000 Mar; 18(6):1378-91. PubMed ID: 10715310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone-modifying agents as adjuvant therapy for early-stage breast cancer.
    Figueroa-Magalhães MC; Miller RS
    Oncology (Williston Park); 2012 Oct; 26(10):955-62. PubMed ID: 23176008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.
    Gralow JR; Barlow WE; Paterson AHG; M'iao JL; Lew DL; Stopeck AT; Hayes DF; Hershman DL; Schubert MM; Clemons M; Van Poznak CH; Dees EC; Ingle JN; Falkson CI; Elias AD; Messino MJ; Margolis JH; Dakhil SR; Chew HK; Dammann KZ; Abrams JS; Livingston RB; Hortobagyi GN
    J Natl Cancer Inst; 2020 Jul; 112(7):698-707. PubMed ID: 31693129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.
    Hadji P; Coleman RE; Wilson C; Powles TJ; Clézardin P; Aapro M; Costa L; Body JJ; Markopoulos C; Santini D; Diel I; Di Leo A; Cameron D; Dodwell D; Smith I; Gnant M; Gray R; Harbeck N; Thurlimann B; Untch M; Cortes J; Martin M; Albert US; Conte PF; Ejlertsen B; Bergh J; Kaufmann M; Holen I
    Ann Oncol; 2016 Mar; 27(3):379-90. PubMed ID: 26681681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates in adjuvant setting for breast cancer: a review of the meta-analysis of bisphosphonates' effects on breast cancer recurrence presented in December 2013 at San Antonio Breast Conference.
    Costa L
    Curr Opin Support Palliat Care; 2014 Dec; 8(4):414-9. PubMed ID: 25319273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
    Lancet; 2015 Oct; 386(10001):1353-1361. PubMed ID: 26211824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Frequency of and Risk Factors for the Use of Bisphosphonates in the Adjuvant Setting of Primary Breast Cancer in Germany.
    Fick EM; Katalinic A; Waldmann A
    Cancer Res Treat; 2015 Oct; 47(4):747-56. PubMed ID: 25672584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.
    Henry NL; Somerfield MR; Abramson VG; Ismaila N; Allison KH; Anders CK; Chingos DT; Eisen A; Ferrari BL; Openshaw TH; Spears PA; Vikas P; Stearns V
    J Clin Oncol; 2019 Aug; 37(22):1965-1977. PubMed ID: 31206315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab and the current status of bone-modifying drugs in breast cancer.
    Lee BL; Higgins MJ; Goss PE
    Acta Oncol; 2012 Feb; 51(2):157-67. PubMed ID: 22150116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Bisphosphonates in Breast Cancer Therapy.
    Goldvaser H; Amir E
    Curr Treat Options Oncol; 2019 Mar; 20(4):26. PubMed ID: 30874905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of bisphosphonates of adjuvant therapy in breast cancer].
    Gálvez-Muñoz E; Rodríguez-Lescure Á
    Med Clin (Barc); 2010 Jun; 135(2):70-4. PubMed ID: 20022069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations.
    Henry NL; Somerfield MR; Abramson VG; Allison KH; Anders CK; Chingos DT; Hurria A; Openshaw TH; Krop IE
    J Clin Oncol; 2016 Jul; 34(19):2303-11. PubMed ID: 27001586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.